Clinical Trial Update: GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing trametinib (GSK1120212) to standard chemotherapy in patients with advanced or metastatic BRAF V600E/K-mutant melanoma. Results from the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GSK1120212 (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2013-03-15